English
简体中文
Total: £ 56.28
Published Date: 2026-03-16 | Pages: 109 | Tables: 113 | Pharma & Healthcare
The global HIV and AIDS Vaccine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HIV and AIDS Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
The North American market for HIV and AIDS Vaccine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for HIV and AIDS Vaccine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of HIV and AIDS Vaccine include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global HIV and AIDS Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HIV and AIDS Vaccine. The HIV and AIDS Vaccine market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global HIV and AIDS Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist HIV and AIDS Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Johnson and Johnson (Janssen)
Sanofi-Pasteur
Uvax Bio
AELIX Therapeutics
IAVI
HKUMed
Segment by Type
Preventive Vaccine
Therapeutic Vaccine
by Application
Viral Vector Vaccines
Recombinant Protein Vaccines
Nucleic Acid Vaccines (including mRNA Vaccines)
Other Vaccines
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for HIV and AIDS Vaccine manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines HIV and AIDS Vaccine sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 HIV and AIDS Vaccine Market Overview
1.1 Product Definition
1.2 HIV and AIDS Vaccine by Type
1.2.1 Global HIV and AIDS Vaccine Market Value by Type: 2025 vs 2032
1.2.2 Preventive Vaccine
1.2.3 Therapeutic Vaccine
1.3 HIV and AIDS Vaccine by Application
1.3.1 Global HIV and AIDS Vaccine Market Value by Application: 2025 vs 2032
1.3.2 Viral Vector Vaccines
1.3.3 Recombinant Protein Vaccines
1.3.4 Nucleic Acid Vaccines (including mRNA Vaccines)
1.3.5 Other Vaccines
1.4 Global HIV and AIDS Vaccine Market Size Estimates and Forecasts
1.4.1 Global HIV and AIDS Vaccine Revenue 2021–2032
1.4.2 Global HIV and AIDS Vaccine Sales 2021–2032
1.4.3 Global HIV and AIDS Vaccine Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 HIV and AIDS Vaccine Market Competition by Manufacturers
2.1 Global HIV and AIDS Vaccine Sales Market Share by Manufacturers (2021–2026)
2.2 Global HIV and AIDS Vaccine Revenue Market Share by Manufacturers (2021–2026)
2.3 Global HIV and AIDS Vaccine Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of HIV and AIDS Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of HIV and AIDS Vaccine, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of HIV and AIDS Vaccine, Product Types and Applications
2.7 Global Key Manufacturers of HIV and AIDS Vaccine, Date of Entry into the Industry
2.8 Global HIV and AIDS Vaccine Market Competitive Situation and Trends
2.8.1 Global HIV and AIDS Vaccine Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global HIV and AIDS Vaccine Players Market Share by Revenue
2.8.3 Global HIV and AIDS Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global HIV and AIDS Vaccine Market Scenario by Region
3.1 Global HIV and AIDS Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global HIV and AIDS Vaccine Sales by Region: 2021–2032
3.2.1 Global HIV and AIDS Vaccine Sales by Region: 2021–2026
3.2.2 Global HIV and AIDS Vaccine Sales by Region: 2027–2032
3.3 Global HIV and AIDS Vaccine Revenue by Region: 2021–2032
3.3.1 Global HIV and AIDS Vaccine Revenue by Region: 2021–2026
3.3.2 Global HIV and AIDS Vaccine Revenue by Region: 2027–2032
3.4 North America HIV and AIDS Vaccine Market Facts & Figures by Country
3.4.1 North America HIV and AIDS Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America HIV and AIDS Vaccine Sales by Country (2021–2032)
3.4.3 North America HIV and AIDS Vaccine Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe HIV and AIDS Vaccine Market Facts & Figures by Country
3.5.1 Europe HIV and AIDS Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe HIV and AIDS Vaccine Sales by Country (2021–2032)
3.5.3 Europe HIV and AIDS Vaccine Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HIV and AIDS Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific HIV and AIDS Vaccine Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific HIV and AIDS Vaccine Sales by Region (2021–2032)
3.6.3 Asia Pacific HIV and AIDS Vaccine Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America HIV and AIDS Vaccine Market Facts & Figures by Country
3.7.1 Latin America HIV and AIDS Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America HIV and AIDS Vaccine Sales by Country (2021–2032)
3.7.3 Latin America HIV and AIDS Vaccine Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa HIV and AIDS Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa HIV and AIDS Vaccine Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa HIV and AIDS Vaccine Sales by Country (2021–2032)
3.8.3 Middle East and Africa HIV and AIDS Vaccine Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global HIV and AIDS Vaccine Sales by Type (2021–2032)
4.1.1 Global HIV and AIDS Vaccine Sales by Type (2021–2026)
4.1.2 Global HIV and AIDS Vaccine Sales by Type (2027–2032)
4.1.3 Global HIV and AIDS Vaccine Sales Market Share by Type (2021–2032)
4.2 Global HIV and AIDS Vaccine Revenue by Type (2021–2032)
4.2.1 Global HIV and AIDS Vaccine Revenue by Type (2021–2026)
4.2.2 Global HIV and AIDS Vaccine Revenue by Type (2027–2032)
4.2.3 Global HIV and AIDS Vaccine Revenue Market Share by Type (2021–2032)
4.3 Global HIV and AIDS Vaccine Price by Type (2021–2032)
5 Segment by Application
5.1 Global HIV and AIDS Vaccine Sales by Application (2021–2032)
5.1.1 Global HIV and AIDS Vaccine Sales by Application (2021–2026)
5.1.2 Global HIV and AIDS Vaccine Sales by Application (2027–2032)
5.1.3 Global HIV and AIDS Vaccine Sales Market Share by Application (2021–2032)
5.2 Global HIV and AIDS Vaccine Revenue by Application (2021–2032)
5.2.1 Global HIV and AIDS Vaccine Revenue by Application (2021–2026)
5.2.2 Global HIV and AIDS Vaccine Revenue by Application (2027–2032)
5.2.3 Global HIV and AIDS Vaccine Revenue Market Share by Application (2021–2032)
5.3 Global HIV and AIDS Vaccine Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Johnson and Johnson (Janssen)
6.1.1 Johnson and Johnson (Janssen) Company Information
6.1.2 Johnson and Johnson (Janssen) Description and Business Overview
6.1.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio
6.1.5 Johnson and Johnson (Janssen) Recent Developments/Updates
6.2 Sanofi-Pasteur
6.2.1 Sanofi-Pasteur Company Information
6.2.2 Sanofi-Pasteur Description and Business Overview
6.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio
6.2.5 Sanofi-Pasteur Recent Developments/Updates
6.3 Uvax Bio
6.3.1 Uvax Bio Company Information
6.3.2 Uvax Bio Description and Business Overview
6.3.3 Uvax Bio HIV and AIDS Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Uvax Bio HIV and AIDS Vaccine Product Portfolio
6.3.5 Uvax Bio Recent Developments/Updates
6.4 AELIX Therapeutics
6.4.1 AELIX Therapeutics Company Information
6.4.2 AELIX Therapeutics Description and Business Overview
6.4.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio
6.4.5 AELIX Therapeutics Recent Developments/Updates
6.5 IAVI
6.5.1 IAVI Company Information
6.5.2 IAVI Description and Business Overview
6.5.3 IAVI HIV and AIDS Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 IAVI HIV and AIDS Vaccine Product Portfolio
6.5.5 IAVI Recent Developments/Updates
6.6 HKUMed
6.6.1 HKUMed Company Information
6.6.2 HKUMed Description and Business Overview
6.6.3 HKUMed HIV and AIDS Vaccine Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 HKUMed HIV and AIDS Vaccine Product Portfolio
6.6.5 HKUMed Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HIV and AIDS Vaccine Industry Chain Analysis
7.2 HIV and AIDS Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HIV and AIDS Vaccine Production Mode & Process Analysis
7.4 HIV and AIDS Vaccine Sales and Marketing
7.4.1 HIV and AIDS Vaccine Sales Channels
7.4.2 HIV and AIDS Vaccine Distributors
7.5 HIV and AIDS Vaccine Customer Analysis
8 HIV and AIDS Vaccine Market Dynamics
8.1 HIV and AIDS Vaccine Industry Trends
8.2 HIV and AIDS Vaccine Market Drivers
8.3 HIV and AIDS Vaccine Market Challenges
8.4 HIV and AIDS Vaccine Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global HIV and AIDS Vaccine Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global HIV and AIDS Vaccine Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global HIV and AIDS Vaccine Market Competitive Situation by Manufacturers in 2025
Table 4. Global HIV and AIDS Vaccine Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global HIV and AIDS Vaccine Sales Market Share by Manufacturers (2021–2026)
Table 6. Global HIV and AIDS Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global HIV and AIDS Vaccine Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market HIV and AIDS Vaccine Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of HIV and AIDS Vaccine, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of HIV and AIDS Vaccine, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of HIV and AIDS Vaccine, Product Types and Applications
Table 12. Global Key Manufacturers of HIV and AIDS Vaccine, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global HIV and AIDS Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on HIV and AIDS Vaccine Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global HIV and AIDS Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global HIV and AIDS Vaccine Sales by Region (K Units), 2021–2026
Table 18. Global HIV and AIDS Vaccine Sales Market Share by Region (2021–2026)
Table 19. Global HIV and AIDS Vaccine Sales by Region (K Units), 2027–2032
Table 20. Global HIV and AIDS Vaccine Sales Market Share by Region (2027–2032)
Table 21. Global HIV and AIDS Vaccine Revenue by Region (US$ Million), 2021–2026
Table 22. Global HIV and AIDS Vaccine Revenue Market Share by Region (2021–2026)
Table 23. Global HIV and AIDS Vaccine Revenue by Region (US$ Million), 2027–2032
Table 24. Global HIV and AIDS Vaccine Revenue Market Share by Region (2027–2032)
Table 25. North America HIV and AIDS Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America HIV and AIDS Vaccine Sales by Country (K Units), 2021–2026
Table 27. North America HIV and AIDS Vaccine Sales by Country (K Units), 2027–2032
Table 28. North America HIV and AIDS Vaccine Revenue by Country (US$ Million), 2021–2026
Table 29. North America HIV and AIDS Vaccine Revenue by Country (US$ Million), 2027–2032
Table 30. Europe HIV and AIDS Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe HIV and AIDS Vaccine Sales by Country (K Units), 2021–2026
Table 32. Europe HIV and AIDS Vaccine Sales by Country (K Units), 2027–2032
Table 33. Europe HIV and AIDS Vaccine Revenue by Country (US$ Million), 2021–2026
Table 34. Europe HIV and AIDS Vaccine Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific HIV and AIDS Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific HIV and AIDS Vaccine Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific HIV and AIDS Vaccine Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific HIV and AIDS Vaccine Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific HIV and AIDS Vaccine Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America HIV and AIDS Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America HIV and AIDS Vaccine Sales by Country (K Units), 2021–2026
Table 42. Latin America HIV and AIDS Vaccine Sales by Country (K Units), 2027–2032
Table 43. Latin America HIV and AIDS Vaccine Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America HIV and AIDS Vaccine Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa HIV and AIDS Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa HIV and AIDS Vaccine Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa HIV and AIDS Vaccine Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa HIV and AIDS Vaccine Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa HIV and AIDS Vaccine Revenue by Country (US$ Million), 2027–2032
Table 50. Global HIV and AIDS Vaccine Sales (K Units) by Type (2021–2026)
Table 51. Global HIV and AIDS Vaccine Sales (K Units) by Type (2027–2032)
Table 52. Global HIV and AIDS Vaccine Sales Market Share by Type (2021–2026)
Table 53. Global HIV and AIDS Vaccine Sales Market Share by Type (2027–2032)
Table 54. Global HIV and AIDS Vaccine Revenue (US$ Million) by Type (2021–2026)
Table 55. Global HIV and AIDS Vaccine Revenue (US$ Million) by Type (2027–2032)
Table 56. Global HIV and AIDS Vaccine Revenue Market Share by Type (2021–2026)
Table 57. Global HIV and AIDS Vaccine Revenue Market Share by Type (2027–2032)
Table 58. Global HIV and AIDS Vaccine Price (US$/Unit) by Type (2021–2026)
Table 59. Global HIV and AIDS Vaccine Price (US$/Unit) by Type (2027–2032)
Table 60. Global HIV and AIDS Vaccine Sales (K Units) by Application (2021–2026)
Table 61. Global HIV and AIDS Vaccine Sales (K Units) by Application (2027–2032)
Table 62. Global HIV and AIDS Vaccine Sales Market Share by Application (2021–2026)
Table 63. Global HIV and AIDS Vaccine Sales Market Share by Application (2027–2032)
Table 64. Global HIV and AIDS Vaccine Revenue (US$ Million) by Application (2021–2026)
Table 65. Global HIV and AIDS Vaccine Revenue (US$ Million) by Application (2027–2032)
Table 66. Global HIV and AIDS Vaccine Revenue Market Share by Application (2021–2026)
Table 67. Global HIV and AIDS Vaccine Revenue Market Share by Application (2027–2032)
Table 68. Global HIV and AIDS Vaccine Price (US$/Unit) by Application (2021–2026)
Table 69. Global HIV and AIDS Vaccine Price (US$/Unit) by Application (2027–2032)
Table 70. Johnson and Johnson (Janssen) Company Information
Table 71. Johnson and Johnson (Janssen) Description and Business Overview
Table 72. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product
Table 74. Johnson and Johnson (Janssen) Recent Developments/Updates
Table 75. Sanofi-Pasteur Company Information
Table 76. Sanofi-Pasteur Description and Business Overview
Table 77. Sanofi-Pasteur HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Sanofi-Pasteur HIV and AIDS Vaccine Product
Table 79. Sanofi-Pasteur Recent Developments/Updates
Table 80. Uvax Bio Company Information
Table 81. Uvax Bio Description and Business Overview
Table 82. Uvax Bio HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Uvax Bio HIV and AIDS Vaccine Product
Table 84. Uvax Bio Recent Developments/Updates
Table 85. AELIX Therapeutics Company Information
Table 86. AELIX Therapeutics Description and Business Overview
Table 87. AELIX Therapeutics HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. AELIX Therapeutics HIV and AIDS Vaccine Product
Table 89. AELIX Therapeutics Recent Developments/Updates
Table 90. IAVI Company Information
Table 91. IAVI Description and Business Overview
Table 92. IAVI HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. IAVI HIV and AIDS Vaccine Product
Table 94. IAVI Recent Developments/Updates
Table 95. HKUMed Company Information
Table 96. HKUMed Description and Business Overview
Table 97. HKUMed HIV and AIDS Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. HKUMed HIV and AIDS Vaccine Product
Table 99. HKUMed Recent Developments/Updates
Table 100. Key Raw Materials Lists
Table 101. Raw Materials Key Suppliers Lists
Table 102. HIV and AIDS Vaccine Distributors List
Table 103. HIV and AIDS Vaccine Customers List
Table 104. HIV and AIDS Vaccine Market Trends
Table 105. HIV and AIDS Vaccine Market Drivers
Table 106. HIV and AIDS Vaccine Market Challenges
Table 107. HIV and AIDS Vaccine Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report
List of Figures
Figure 1. Product Picture of HIV and AIDS Vaccine
Figure 2. Global HIV and AIDS Vaccine Market Value by Type (US$ Million), 2021–2032
Figure 3. Global HIV and AIDS Vaccine Market Share by Type: 2025 & 2032
Figure 4. Preventive Vaccine Product Picture
Figure 5. Therapeutic Vaccine Product Picture
Figure 6. Global HIV and AIDS Vaccine Market Value by Application (US$ Million), 2021–2032
Figure 7. Global HIV and AIDS Vaccine Market Share by Application: 2025 & 2032
Figure 8. Viral Vector Vaccines
Figure 9. Recombinant Protein Vaccines
Figure 10. Nucleic Acid Vaccines (including mRNA Vaccines)
Figure 11. Other Vaccines
Figure 12. Global HIV and AIDS Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global HIV and AIDS Vaccine Market Size (US$ Million), 2021–2032
Figure 14. Global HIV and AIDS Vaccine Sales (K Units), 2021–2032
Figure 15. Global HIV and AIDS Vaccine Average Price (US$/Unit), 2021–2032
Figure 16. HIV and AIDS Vaccine Report Years Considered
Figure 17. HIV and AIDS Vaccine Sales Share by Manufacturers in 2025
Figure 18. Global HIV and AIDS Vaccine Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global HIV and AIDS Vaccine Players: Market Share by Revenue in HIV and AIDS Vaccine in 2025
Figure 20. HIV and AIDS Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global HIV and AIDS Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America HIV and AIDS Vaccine Sales Market Share by Country (2021–2032)
Figure 23. North America HIV and AIDS Vaccine Revenue Market Share by Country (2021–2032)
Figure 24. United States HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe HIV and AIDS Vaccine Sales Market Share by Country (2021–2032)
Figure 27. Europe HIV and AIDS Vaccine Revenue Market Share by Country (2021–2032)
Figure 28. Germany HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific HIV and AIDS Vaccine Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific HIV and AIDS Vaccine Revenue Market Share by Region (2021–2032)
Figure 35. China HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America HIV and AIDS Vaccine Sales Market Share by Country (2021–2032)
Figure 43. Latin America HIV and AIDS Vaccine Revenue Market Share by Country (2021–2032)
Figure 44. Mexico HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa HIV and AIDS Vaccine Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa HIV and AIDS Vaccine Revenue Market Share by Country (2021–2032)
Figure 50. Turkey HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE HIV and AIDS Vaccine Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of HIV and AIDS Vaccine by Type (2021–2032)
Figure 54. Global Revenue Market Share of HIV and AIDS Vaccine by Type (2021–2032)
Figure 55. Global HIV and AIDS Vaccine Price (US$/Unit) by Type (2021–2032)
Figure 56. Global Sales Market Share of HIV and AIDS Vaccine by Application (2021–2032)
Figure 57. Global Revenue Market Share of HIV and AIDS Vaccine by Application (2021–2032)
Figure 58. Global HIV and AIDS Vaccine Price (US$/Unit) by Application (2021–2032)
Figure 59. HIV and AIDS Vaccine Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
